Core Insights - Jazz Pharmaceuticals plc will report its 2025 third quarter financial results on November 5, 2025, after U.S. market close, followed by a live audio webcast for discussion [1] - The company is focused on developing life-changing medicines for serious diseases, with a diverse portfolio including therapies for sleep disorders, epilepsy, and a growing range of cancer treatments [2] Financial Reporting - The financial results will be discussed in a live audio webcast scheduled for 4:30 p.m. EST / 9:30 p.m. GMT [1] - Interested parties can register for the call in advance to ensure timely connection [2] Company Overview - Jazz Pharmaceuticals is a global biopharma company headquartered in Dublin, Ireland, dedicated to innovative research and development in oncology and neuroscience [2] - The company has a robust pipeline of innovative therapeutics and is committed to serving patients worldwide [2] Recent Developments - The FDA has approved Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) combination as first-line maintenance therapy for extensive-stage small cell lung cancer [4] - New real-world evidence and Phase 4 data for Xywav® (calcium, magnesium, potassium, and sodium oxybates) have been showcased, reinforcing its treatment effects [5][6]